Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 2
1972 1
1982 1
1983 1
2000 4
2001 5
2002 6
2003 8
2004 5
2005 9
2006 4
2007 11
2008 20
2009 18
2010 18
2011 16
2012 26
2013 18
2014 21
2015 38
2016 28
2017 33
2018 27
2019 29
2020 33
2021 41
2022 20
Text availability
Article attribute
Article type
Publication date

Search Results

395 results
Results by year
Filters applied: . Clear all
Page 1
Past, Present and Future of Oncolytic Reovirus.
Müller L, Berkeley R, Barr T, Ilett E, Errington-Mais F. Müller L, et al. Cancers (Basel). 2020 Oct 31;12(11):3219. doi: 10.3390/cancers12113219. Cancers (Basel). 2020. PMID: 33142841 Free PMC article. Review.
Mechanistic studies of oncolytic viruses (OVs) have revealed that most, if not all, OVs induce direct oncolysis and stimulate innate and adaptive anti-tumour immunity. With the advancement of tumour modelling, allowing characterisation of the effects of tumour microenviron …
Mechanistic studies of oncolytic viruses (OVs) have revealed that most, if not all, OVs induce direct oncolysis and stimulate innate …
Role of Myeloid Cells in Oncolytic Reovirus-Based Cancer Therapy.
Kumar V, Giacomantonio MA, Gujar S. Kumar V, et al. Viruses. 2021 Apr 10;13(4):654. doi: 10.3390/v13040654. Viruses. 2021. PMID: 33920168 Free PMC article. Review.
Oncolytic reovirus preferentially targets and kills cancer cells via the process of oncolysis, and additionally drives clinically favorable antitumor T cell responses that form protective immunological memory against cancer relapse. This two-prong attack by reovi
Oncolytic reovirus preferentially targets and kills cancer cells via the process of oncolysis, and additionally drives clinica
Oncolytic virus therapy: A new era of cancer treatment at dawn.
Fukuhara H, Ino Y, Todo T. Fukuhara H, et al. Cancer Sci. 2016 Oct;107(10):1373-1379. doi: 10.1111/cas.13027. Epub 2016 Sep 9. Cancer Sci. 2016. PMID: 27486853 Free PMC article. Review.
T-Vec (talimogene laherparepvec), a second-generation oncolytic herpes simplex virus type 1 (HSV-1) armed with GM-CSF, was recently approved as the first oncolytic virus drug in the USA and Europe. ...It appears that it will not be long before oncolytic virus …
T-Vec (talimogene laherparepvec), a second-generation oncolytic herpes simplex virus type 1 (HSV-1) armed with GM-CSF, was recently a …
Oncolytic reovirus-mediated killing of mouse cancer-associated fibroblasts.
Kurisu N, Kaminade T, Eguchi M, Ishigami I, Mizuguchi H, Sakurai F. Kurisu N, et al. Int J Pharm. 2021 Dec 15;610:121269. doi: 10.1016/j.ijpharm.2021.121269. Epub 2021 Nov 5. Int J Pharm. 2021. PMID: 34748806
Oncolytic reovirus, which is a non-enveloped virus that contains 10-segmented double-stranded RNA genome, shows efficient tumor cell lysis without apparent cytotoxicity to normal cells and has been tested worldwide in clinical trials against various types of tumors.
Oncolytic reovirus, which is a non-enveloped virus that contains 10-segmented double-stranded RNA genome, shows efficient tumo
Oncolytic reovirus induces ovarian cancer cell apoptosis in a TLR3-dependent manner.
An Y, Wang X, Wu X, Chen L, Yang Y, Lin X, Wang N, Duan J, Long S, Zhao X. An Y, et al. Virus Res. 2021 Aug;301:198440. doi: 10.1016/j.virusres.2021.198440. Epub 2021 Apr 30. Virus Res. 2021. PMID: 33940002
In order to solve this resistance problem in the treatment of ovarian cancer, we selected the reovirus-resistant OV-90 ovarian cancer cells to study reovirus oncolytic effects. ...Together, these results demonstrate that reovirus dsRNA induces reovi
In order to solve this resistance problem in the treatment of ovarian cancer, we selected the reovirus-resistant OV-90 ovarian cancer …
Oncolytic Reovirus (pelareorep) Induces Autophagy in KRAS-mutated Colorectal Cancer.
Jiffry J, Thavornwatanayong T, Rao D, Fogel EJ, Saytoo D, Nahata R, Guzik H, Chaudhary I, Augustine T, Goel S, Maitra R. Jiffry J, et al. Clin Cancer Res. 2021 Feb 1;27(3):865-876. doi: 10.1158/1078-0432.CCR-20-2385. Epub 2020 Nov 9. Clin Cancer Res. 2021. PMID: 33168658 Free PMC article. Clinical Trial.
Strategic Combinations: The Future of Oncolytic Virotherapy with Reovirus.
Zhao X, Chester C, Rajasekaran N, He Z, Kohrt HE. Zhao X, et al. Mol Cancer Ther. 2016 May;15(5):767-73. doi: 10.1158/1535-7163.MCT-15-0695. Epub 2016 Apr 14. Mol Cancer Ther. 2016. PMID: 27197256 Review.
Reovirus therapy is currently being tested in combination with radiotherapy, chemotherapy, immunotherapy, and surgery. In this review, we discuss the current successes of these combinatorial therapeutic strategies and emphasize the importance of prioritizing combination
Reovirus therapy is currently being tested in combination with radiotherapy, chemotherapy, immunotherapy, and surgery. In this review
Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors.
Annels NE, Simpson GR, Denyer M, Arif M, Coffey M, Melcher A, Harrington K, Vile R, Pandha H. Annels NE, et al. Mol Ther Oncolytics. 2020 Oct 4;20:434-446. doi: 10.1016/j.omto.2020.09.010. eCollection 2021 Mar 26. Mol Ther Oncolytics. 2020. PMID: 33665363 Free PMC article.
We investigated whether the combination of intratumoral oncolytic reovirus, followed by targeted blockade of Programmed cell death protein 1 (PD-1) checkpoint inhibition and/or the immunomodulatory CD73/Adenosine system can enhance anti-tumor immunity. Treatment of …
We investigated whether the combination of intratumoral oncolytic reovirus, followed by targeted blockade of Programmed cell d …
Delivery of Oncolytic Reovirus by Cell Carriers.
Ilett EJ. Ilett EJ. Methods Mol Biol. 2020;2058:229-236. doi: 10.1007/978-1-4939-9794-7_14. Methods Mol Biol. 2020. PMID: 31486041 Free article.
However, as single agents oncolytic viruses have shown only moderate clinical benefit and many challenges remain before their full potential is realized. Central to this is the efficient delivery of the virus to the tumor site and potentiation of the antitumor immune respo …
However, as single agents oncolytic viruses have shown only moderate clinical benefit and many challenges remain before their full po …
Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer.
Kyula JN, Roulstone V, Karapanagiotou EM, Melcher AA, Harrington KJ. Kyula JN, et al. Expert Opin Biol Ther. 2012 Dec;12(12):1669-78. doi: 10.1517/14712598.2012.745507. Expert Opin Biol Ther. 2012. PMID: 23140488 Review.
AREAS COVERED: In this review, we discuss the pre-clinical and clinical data that have underpinned the translational development of oncolytic reovirus thus far. In particular, we describe the iterative nature of the research programme through initial studies testing …
AREAS COVERED: In this review, we discuss the pre-clinical and clinical data that have underpinned the translational development of oncol
395 results